| Literature DB >> 36193295 |
Wenting Gong1, Wen Tang2, Zhengjiang Jin3, Ronghao Zheng4, Lan Luo5, Furong Zhang1, Chenyang Cai1, Jiangyan Zhang1, Xiaolin Wu4, Jianping Shang4, Xiaolan Shu2, Ting Wang6, Danna Tu7.
Abstract
Purpose: To explore the trends and correlation between antibiotics consumption and antimicrobial resistance in children in a specialist hospital from 2016-2021 in China. Patients andEntities:
Keywords: antibiotic consumption; antimicrobial resistance; children; correlation
Year: 2022 PMID: 36193295 PMCID: PMC9526424 DOI: 10.2147/IDR.S381604
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.177
Trends of Annual Consumption of Antibiotics in the Specialist Children’s Hospital During 2016–2021
| Categories of Antibiotics | Annual Antibiotics Consumption (DDDs/1000 Patient-Days) | Linear Regression | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | Slope ( | Trend | ||
| Penicillins (except for P/BLI combinations) | 19.98 | 24.77 | 17.11 | 21.51 | 48.96 | 42.81 | 5.461 | 0.075 | Stable |
| P/BLI combinations | 1.11 | 0.29 | 0.67 | 0.65 | 0.79 | 2.37 | 0.222 | 0.238 | Stable |
| First-generation cephalosporins | 1.19 | 0.82 | 0.73 | 1.37 | 1.39 | 3.41 | 0.384 | 0.098 | Stable |
| Second-generation cephalosporins | 3.04 | 2.48 | 4.1 | 1.78 | 2.15 | 3.48 | −0.032 | 0.898 | Stable |
| Third-generation cephalosporins | 4.24 | 5.31 | 6.81 | 7.27 | 5.99 | 18.99 | 2.179 | 0.087 | Stable |
| Fourth-generation cephalosporins | 0.01 | 0 | 0 | 0.03 | 0 | 0 | −0.001 | 0.868 | Stable |
| Cephalosporins (except for C/BLI combinations) | 8.47 | 8.61 | 11.64 | 10.45 | 9.53 | 25.88 | 2.532 | 0.116 | Stable |
| C/BLI combinations | 55.79 | 58.04 | 64.42 | 62.18 | 99.58 | 209.11 | 25.399 | 0.059 | Stable |
| BL/BLI combinations | 56.9 | 58.33 | 65.09 | 62.83 | 100.37 | 211.48 | 25.622 | 0.060 | Stable |
| Carbapenems | 7.82 | 6.41 | 6.99 | 7.57 | 12.32 | 17.25 | 1.870 | 0.044 | Increasing |
| Monobactams | 1.82 | 2.61 | 2.81 | 2.86 | 3.41 | 7.16 | 0.833 | 0.044 | Increasing |
| Macrolides | 95.12 | 77.54 | 74.05 | 73.56 | 41.4 | 66.32 | −7.226 | 0.073 | Stable |
| Glycopeptide antibacterials | 1.72 | 1.48 | 1.11 | 0.94 | 2.98 | 4.2 | 0.478 | 0.117 | Stable |
| Oxazolidinone | 7.87 | 4.94 | 2.44 | 4.96 | 3.13 | 2.57 | −0.840 | 0.080 | Stable |
| Imidazole derivatives | 2.34 | 3.39 | 4.13 | 3.26 | 2.21 | 3.45 | 0.033 | 0.875 | Stable |
| Quinolones | 0.03 | 0.21 | 0.26 | 0.25 | 0.14 | 0.47 | 0.057 | 0.105 | Stable |
| Antifungal drugs | 5.44 | 18.9 | 5.81 | 5.71 | 4.01 | 6.08 | −1.188 | 0.432 | Stable |
| Sodium fusidate | 0.63 | 0.3 | 0.13 | 0.2 | 0.24 | 0.27 | −0.055 | 0.222 | Stable |
| Aminoglycosides | 0.1 | 0 | 0 | 0 | 0.01 | 3.66 | 0.509 | 0.170 | Stable |
| Nitrofuran derivatives | 0 | 0 | 0 | 0 | 0 | 0.04 | 0.006 | 0.158 | Stable |
| Sulfonamides and trimethoprim, Lincosamides, Streptogramins and Tetracycline | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - |
Abbreviations: BL/BLI, β-lactam/β-lactamase inhibitor; C/BLI, cephalosporin/β-lactamase inhibitor; P/BLI, penicillin/β-Lactamase inhibitor; DDDs, defined daily doses.
Figure 1Annual trends of certain antimicrobial resistance rates during the study period. (A) Annual trends of resistance rates of E.faecium to ciprofloxacin, (S)pneumoniae to ceftriaxone and A.baumannii to carbapenems. (B) Annual trends of resistance rates of E.cloacae to carbapenems, (P)aeruginosa to ceftazidime and E.coli to cefepime and E.coli to carbapenems.
Figure 2Associations between antibiotics consumption and antimicrobial resistance rates during the study period. (A) Correlation between C/BLI combinations and A.baumannii to carbapenems, E.cloacae to carbapenems and P.aeruginosa to ceftazidime. (B) Correlation between Carbapenems and A.baumannii to carbapenems, E.cloacae to carbapenems and P.aeruginosa to ceftazidime. (C) Correlation between Monobactams and A.baumannii to carbapenems and E.cloacae to carbapenems. The DDDs are shown on the left y-axis while the resistance rates are shown on the right y-axis.